This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Peptidedrug conjugates (PDCs) were produced by combining a cancer selective cell-penetrating peptide (PDIP) with camptothecin (CPT). The PDCs crossed membranes and cleavable PDCs killed melanoma cells with nanomolar potency. ABSTRACT Drug targeting strategies, such as peptidedrug conjugates (PDCs), have arisen to combat the issue of off-target toxicity that is commonly associated with chemotherapeutic small molecule drugs.
A global survey spanning 68 countries reveals that public trust in scientists is still high. A team of 241 researchers conducted the largest post-pandemic study of trust in science, societal expectations and public views on research priorities.
MONDAY, Jan. 20, 2025 -- Many more Americans are turning to ketamine for kicks, a new study reports.Recreational use of the anesthetic drug among U.S. adults increased 40% between 2021 and 2022, researchers say.That follows a nearly 82% increase in.
A new study has described a phenomenon researchers refer to as 'contagious urinations.' The study in 20 captive chimpanzees living at the Kumamoto Sanctuary in Japan shows that, when one chimp pees, others are more likely to follow.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
A depression database was first constructed, and simvastatin was used as an input to predict potential targets using machine/deep learning methods. Interestingly, the P2X7/NLRP3 pathway was predicted as a potential target for simvastatin. Subsequent Animal experiment's results confirmed this predict. ABSTRACT Depression is a mental health disorder and is the fourth most prevalent disease.
Over half of our genomes consists of thousands of remnants of ancient viral DNA, known as transposable elements, which are widespread across the tree of life. Once dismissed as the 'dark side' of the genome, researchers have now revealed their crucial role in early embryo development.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Over half of our genomes consists of thousands of remnants of ancient viral DNA, known as transposable elements, which are widespread across the tree of life. Once dismissed as the 'dark side' of the genome, researchers have now revealed their crucial role in early embryo development.
MONDAY, Jan. 20, 2025 -- It turns out, your protein powder might not be as healthy as you think.A new report from the Clean Label Project reveals that popular protein powders -- especially plant-based, organic and chocolate-flavored varieties --.
In 2023, a small pharmaceutical company faced a critical Refusal-to-File (RTF) decision from the FDA for their New Drug Application (NDA). The letter outlined numerous deficiencies, including incomplete stability data, poorly organized information, and inconsistencies in the Chemistry, Manufacturing, and Controls (CMC) section.
The Hidden Pitfalls of Searching Drug Patents: What You Need to Know As a professional in the pharmaceutical industry, you're likely no stranger to the importance of staying on top of the latest patent developments. But have you ever stopped to think about the potential pitfalls of searching for drug patents on Google Patents? At first glance, Google Patents may seem like a convenient and user-friendly resource for searching patent data.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
As Salesforce prepares to roll out its Spring ’25 release, its vital to stay ahead of the curve. These updates bring new features, enhanced security, and changes that may impact existing configurations. By proactively testing and preparing your Salesforce org, you can ensure a smooth transition and minimize disruptions. Below, we outline preparation tips and key updates to help you get ready.
Salesforce enforces release updates during each major release cycle, which may alter the behavior of specific features or products. To ensure smooth operations, it’s essential to prepare by testing these updates in a sandbox environment before they are automatically enabled in your production environment starting January 2025. Image Source: Salesforce Preparation Steps Test in Sandbox First Enable release updates in a sandbox to identify potential impacts on your system or workflows.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Salesforce introduces release updates in every cycle, which may modify how specific features or products behave. To ensure a smooth transition, its crucial to test these updates in a sandbox environment before they are activated in your production system. This is especially important as these updates will take effect from January 2025. Steps to Prepare Use a Sandbox for Testing: Enable updates in a sandbox environment to evaluate their impact on your systems and processes before deploying them l
The Salesforce Spring ’25 release is just around the corner, bringing a mix of exciting new features, critical updates, and changes designed to enhance the platforms usability and security. However, with each new release comes the responsibility of preparation, ensuring that your Salesforce environment remains seamless and efficient. Whether you’re a developer, admin, or end user, staying informed and proactive is key to leveraging these updates to their full potential.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
By Sophia R. Gaulkin & Ritte van Laack Readers of this blog likely are familiar with the ongoing, often contentious battle over the labeling of plant-based foods (see, e.g., here , here , and here ). Nearly two years after FDA issued draft guidance on Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements , on January 6, 2025, FDA released draft guidance document on plant-based labeling, Labeling Plant-Based Alternatives to Animal-Derived Foods.
As noted by Bridget Van Kralingen, a senior vice president at IBM, The last best experience that anyone has anywhere becomes the minimum expectation for the experience they want everywhere. Our team often calls this the Amazon effect, because todays consumers expect the easy, intuitive experience they have shopping on Amazon everywhere they go on the internet including with their health insurance provider.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Informa Connect's Patient Assistance & Access Programs (PAP) March 18-20, 2025 | Sheraton Philadelphia Downtown PA Pre-Conference Workshops on March 17, 2025 Drug Channels readers save 10% on their registration with code 25DC10 When it comes to patient affordability, its difficult to imagine a more complex time for our industry. Navigating policy updates, disarming AFPs, considering compliance risks There are countless barriers to medication access and it remains our responsibility as an in
The oncology drug development landscape is evolving rapidly, driven by the deployment of targeted therapies in precision medicine and regulatory initiatives like the FDAs Project Optimus. These advances are reshaping how pharmaceutical and biotechnology companies approach clinical trial design, with a focus on patient-centric dosing strategies. This article explores how innovations in precision medicine are reshaping clinical trials, followed by a discussion on Project Optimus and its impact on
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
187 
Let's personalize your content